Pfizer will buy the stake in Valneva, which is also working on its COVID-19 vaccine, at a price of 9.49 euros per share, via a reserved capital increase.Register now for FREE unlimited access to Reuters.comValneva will use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program.
"Pfizer's investment in Valneva highlights the quality of the work that we’ve done together over the past two years and is a strong recognition of Valneva's vaccine expertise," said Valneva chief executive Thomas Lingelbach.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Get some more jabs in you. The 8th or 9th booster will work